Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
The Second Clinical Medical College, Shanxi Medical University, Second Hospital of Shanxi Medical University, Taiyuan, China.
Front Endocrinol (Lausanne). 2023 Feb 17;14:1113611. doi: 10.3389/fendo.2023.1113611. eCollection 2023.
The purpose of this study was to assess the incidence of type 2 diabetes mellitus (T2DM) after 6 years in patients with IGT who received early probiotic intervention in the Probiotics Prevention Diabetes Program (PPDP) trial.
77 patients with IGT in the PPDP trial were randomized to either probiotic or placebo. After the completion of the trial, 39 non-T2DM patients were invited to follow up glucose metabolism after the next 4 years. The incidence of T2DM in each group was assessed using Kaplan-Meier analysis. The 16S rDNA sequencing technology was used to analyze gut microbiota's structural composition and abundance changes between the groups.
The cumulative incidence of T2DM was 59.1% with probiotic treatment versus 54.5% with placebo within 6 years, there was no significant difference in the risk of developing T2DM between the two groups (=0.674).
Supplemental probiotic therapy does not reduce the risk of IGT conversion to T2DM.
https://www.chictr.org.cn/showproj.aspx?proj=5543, identifier ChiCTR-TRC-13004024.
本研究旨在评估在 Probiotics Prevention Diabetes Program（PPDP）试验中接受早期益生菌干预的 IGT 患者在 6 年后发生 2 型糖尿病（T2DM）的发生率。
PPDP 试验中 77 例 IGT 患者被随机分为益生菌组或安慰剂组。试验结束后，邀请 39 例非 T2DM 患者在接下来的 4 年内随访葡萄糖代谢情况。采用 Kaplan-Meier 分析评估两组 T2DM 的发生率。采用 16S rDNA 测序技术分析两组间肠道微生物群结构组成和丰度变化。
益生菌治疗组和安慰剂组在 6 年内 T2DM 的累积发生率分别为 59.1%和 54.5%，两组 T2DM 的发病风险无显著差异（=0.674）。
补充益生菌治疗并不能降低 IGT 向 T2DM 的转化风险。
https://www.chictr.org.cn/showproj.aspx?proj=5543，标识符 ChiCTR-TRC-13004024。
